Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

FIVE at FIVE: Darktrace faces down short sellers; Starbucks caf-fiends; Entain raises guidance; GSK beats the street

Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news

1. Darktrace shoots back at shock claims made by US-based short seller

New York firm Quintessential Capital Markets purports that Darktrace is engaging in similar behaviour to Autonomy, the software company established by Mike Lynch

Read more

2. Starbucks coffee found to be weaker than tea

Costa coffee, owned by beverage giant Coca-Cola, was found to contain 325mg of caffeine in its strongest medium cappuccino, dwarfing Starbucks’ 66mg.

Read more

3. FTSE 100 finishes in negative territory as investors await US Fed decision

At the close, the FTSE 100 had lost 11 points to finish 0.1% lower at 7,761.

Read more

4. Entain raises guidance as World Cup draws in punters

The owner of Coral and Ladbrokes now expects 2022 group EBITDA between £985mln to £995mln, well ahead of the £925mln to £975mln range given in October.

Read more

5. GSK 'beats the Street'; enters 2023 with strong momentum

The pharma giant, which spun out its Haleon consumer business last summer, posted adjusted earnings of 25.8p per share on revenues of around £7.4bn.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK